

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.

## **Cyxone publishes prospectus due to the upcoming rights issue**

The board of directors of Cyxone AB (“Cyxone” or the “Company”) has, in connection with the Company's upcoming rights issue that was announced on 21 December 2021 (the “Rights Issue”), prepared an EU Growth Prospectus (the “Prospectus”), which today has been approved and registered by the Swedish Financial Supervisory Authority (Sw. *Finansinspektionen*).

### **Publishing of the Prospectus**

The Prospectus has been prepared in connection with the Rights Issue and has today, 23 December 2021, been approved and registered by the Swedish Financial Supervisory Authority. The Prospectus, containing complete terms and conditions regarding the Rights Issue, is available on Cyxone's website ([www.cyxone.com](http://www.cyxone.com)) and Vator Securities AB's website ([www.vatorsecurities.se](http://www.vatorsecurities.se)). The prospectus will also be available on the Swedish Financial Supervisory Authority's website ([www.fi.se](http://www.fi.se)).

### **The Rights Issue in brief**

- The right to subscribe for shares with preferential rights shall vest in those who are registered as shareholders in the Company on the record date, 29 December 2021, where five (5) existing shares entitle to three (3) subscription rights and one (1) subscription right entitles to subscription of one (1) share.
- The subscription price is SEK 1.75 per share, which means that Cyxone, provided that the Rights Issue is fully subscribed, will receive approximately SEK 66.9 million before issue costs.
- Cyxone has received subscription commitments from the Company's CEO, Tara Heitner, and CFO, Henrik Hang, amounting to approximately SEK 0.1 million in total, corresponding to approximately 0.1 percent of the Rights Issue. Further, the Company has entered into agreements on guarantee commitments where external investors have undertaken to subscribe for shares in the Rights Issue up to an amount of approximately SEK 60.8 million, corresponding to approximately 91.0 percent of the Rights Issue.
- The subscription period in the Rights Issue runs during 3 January – 21 January 2022.

- Trading in subscriptions rights is expected to take place on Nasdaq First North Growth Market during 3 January – 18 January 2022. Subscription rights that are not utilized during the subscription period will become invalid and lose their value.
- Trading in BTA (Sw. betald tecknad aktie) will take place on Nasdaq First North Growth Market as from and including 3 January 2022 until the Swedish Companies Registration Office (Sw. Bolagsverket) has registered the Rights Issue. This registration is expected to take place during week 5, 2022.

For further information on the Rights Issue, please refer to the published Prospectus.

### **Advisers**

Vator Securities AB acts as financial adviser and Setterwalls Advokatbyrå AB acts as legal adviser to the Company in connection with the Rights Issue. Vator Securities AB also acts as issuer agent in connection with the Rights Issue.

### **Contact**

Tara Heitner, CEO  
Tel: +46 70 781 88 08  
Email: [tara.heitner@cyxone.com](mailto:tara.heitner@cyxone.com)  
Adelgatan 21  
211 22 Malmö, Sweden

*The information was submitted for publication, through the agency of the contact person set out above, at 10.20 a.m. CET on 23 December 2021.*

### **About Cyxone**

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB, +46(0)8-528 00 399, [info@fnca.se](mailto:info@fnca.se). For more information, please visit [www.cyxone.com](http://www.cyxone.com)

### **IMPORTANT INFORMATION**

The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares or other securities in Cyxone. No action has been taken and measures will not be taken to permit a public offering in any jurisdictions other than Sweden. Any invitation to the persons concerned to subscribe for shares in Cyxone will only be made through the Prospectus published by the Company on 23 December 2021. The Prospectus has been approved and registered by the Swedish Financial Supervisory Authority and has been published on the Company's website ([www.cyxone.com](http://www.cyxone.com)). The approval of the Prospectus by the Swedish Financial Supervisory Authority shall not be regarded as an approval of the shares or any other securities. This release is however not a prospectus in accordance to the definition in the Prospectus Regulation (EU) 2017/1129 ("Prospectus Regulation") and this announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in shares or other securities in Cyxone. In order for investors to fully

understand the potential risks and benefits associated with a decision to participate in the Rights Issue, any investment decision should only be made based on the information in the Prospectus. Thus, investors are encouraged to review the Prospectus in its entirety. In accordance with article 2 k of the Prospectus Regulation this press release constitutes an **advertisement**.

The information in this press release may not be released, distributed or published, directly or indirectly, in or into the United States of America, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, South Korea, Switzerland or any other jurisdiction in which such action would be unlawful or would require registration or any other measures than those required by Swedish law. Actions in violation of these restrictions may constitute a violation of applicable securities laws. No shares or other securities in Cyxone have been registered, and no shares or other securities will be registered, under the United States Securities Act of 1933, as amended (the **“Securities Act”**) or the securities legislation of any state or other jurisdiction in the United States of America and no shares or other securities may be offered, sold or otherwise transferred, directly or indirectly, in or into the United States of America, except under an available exemption from, or in a transaction not subject to, the registration requirements under the Securities Act and in compliance with the securities legislation in the relevant state or any other jurisdiction of the United States of America.

Within the European Economic Area (“**EEA**”), no public offering of shares or other securities (“**Securities**”) is made in other countries than Sweden. In other member states of the EU, such an offering of Securities may only be made in accordance with the Prospectus Regulation. In other member states of the EEA which have implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption in the Prospectus Regulation and/or in accordance with an applicable exemption under a relevant national implementation measure. In other member states of the EEA which have not implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption under national law.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” (within the meaning of the United Kingdom version of the EU Prospectus Regulation (2017/1129/ EU) which is part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018) who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the **“Order”**); (ii) high net worth entities etc. falling within Article 49(2)(a) to (d) of the Order; or (iii) such other persons to whom such investment or investment activity may lawfully be made available under the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

This press release may contain forward-looking statements which reflect the Company’s current view on future events and financial and operational development. Words such as “*intend*”,

“expect”, “anticipate”, “may”, “believe”, “plan”, “estimate” and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the actual outcome could differ materially from the forward-looking statements.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.